According to a Jan. 28 update from Baxter, the organization has now restarted all of the site’s 10 manufacturing lines.
The announcement said, “While some lines require additional time to ramp up production, we currently expect to be producing at pre-hurricane levels across the plant early in the first quarter of 2025.”
Baxter attributes this success to the resilience of its teams and coordinating with the FDA.
